HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China.
- HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China.
- The Phase II stage of the study is to evaluate the safety and preliminary efficacy of sovleplenib in adult patients with wAIHA.
- If results of the Phase II stage are positive, the Phase III stage will be initiated to confirm such efficacy and safety.
- Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk.